Helping to drive this growth is Eli Lilly's concerted effort to bolster GLP-1 production. The company expects to produce at least 60% more salable doses of incretins in the first half of 2025 than ...

Viking Therapeutics: "I prefer Eli Lilly." First Solar: "It is a very inexpensive stock." RadNet: "This group is just not strong enough, that includes this one. Let's give it a pause for a second ...

Actress Lily Collins and director Charlie McDowell welcome their first child via surrogacy, highlighting gratitude towards ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said First Solar, Inc. FSLR is a “very inexpensive” stock. First Solar, meanwhile, will report financial results for the fourth quarter ...

Earnings Report 5.125 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 5.041 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.723 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

After Lily Collins and husband Charlie McDowell welcomed their first child via surrogate, the director is shutting down criticism regarding their “path to having a baby.” “Thank you for all the kind ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...